From academic lab to FDA clearance
Validated in a rigorous clinical trial, Osteoboost received FDA clearance in 2024 as the first non-drug therapy for low bone density.
University-led trial Conducted by researchers at the University of Nebraska Medical Center, a top academic medical institution.
Breakthrough Device status Designated a Breakthrough Device by the FDA for providing a more effective treatment for osteopenia.
Gold-standard study design A randomized, double-blinded, sham-controlled study—meeting the highest standard in clinical research.
FDA De Novo clearance Cleared in 2024 as the first non-drug wearable device to treat osteopenia in postmenopausal women.
The science behind Osteoboost’s vibration therapy
Osteoboost was designed to deliver precise mechanical stimulation to the hips and spine—two of the most fracture-prone areas in postmenopausal women. Inspired by decades of biomechanics research, including NASA-funded studies, this therapy uses low-magnitude, high-frequency vibration shown to benefit bone health. Our clinical trial proved the science: targeted vibration significantly slowed bone loss.
The results speak for themselves
Significant reductions in bone loss were observed among participants who adhered to the treatment protocol.
85% reduction in vertebral bone density loss
Participants who used Osteoboost at least 3 times per week saw an 85% reduction in loss of vertebral bone density after 12 months, compared to the placebo group.
83% reduction in vertebral bone strength loss
Participants who used Osteoboost at least 3 times per week saw an 83% reduction in loss of vertebral bone strength after 12 months, compared to the placebo group.
Safe.
Comfortable.
Easy-to-use.
Osteoboost demonstrated an excellent safety profile and high patient adherence.
Scientific advisors and investigators
We’re honored to work with top experts in the areas of bone health and osteoporosis to research and validate Osteoboost’s unique vibration therapy.
Dr. Harold Rosen, MD
Harvard Medical School, Beth Israel Deaconess Medical Center
Professor of Endocrinology at Harvard Medical School, Director Osteoporosis Prevention and Treatment Center at Beth Israel Deaconess Medical Center, leading expert in bone densitometry, biochemical markers of bone turnover and metabolic bone disease.
Dr. David B. Karpf, MD
Stanford University School of Medicine
Professor of Endocrinology at Stanford University School of Medicine, Director Stanford Osteoporosis and Metabolic Bone Disease Clinic, leading researcher on osteoporosis medications (Fosomax trial) and board member of American Bone Health.
Dr. Laura Bilek, PhD, PT
University of Nebraska Medical Center
Associate Dean for Research in the College of Allied Health Professions at the University of Nebraska Medical Center (UNMC). Expert in clinical research for the treatment of low bone mass.
Dr. Tony Keaveny, PhD
University of California Berkeley
Professor of Mechanical Engineering and Bioengineering, UC Berkeley, director of the Berkeley Orthopaedic Biomechanics Lab; Expert in bone mechanics and inventor of VirtuOst.
